1997 FDA FORUM ON REGULATORY SCIENCES
A Culture of Science at FDA: Partnerships in Research and Review
December 9, 1997
SIGMA XI POSTER SESSION
December 8-9, 1997
Natcher Conference Center, NIH, Bethesda, Maryland
FORUM OVERVIEW
You are invited and encouraged to attend the 1997 FDA Forum on Regulatory
Sciences on December 9, 1997, at the Natcher Center at NIH. This year's forum
will examine the relationship between the research and review/regulatory
functions of FDA, an area highlighted in the Science Board Subcommittee on FDA
Research Final Report.
The morning session will include a keynote address by Dr. William Haseltine,
chairman and C.E.O. of Human Genome Sciences; an EPA persective on research
and review from Dr. Penny Fenner-Crisp; and a vision of an ideal research-
review interaction by Dr. Bernard Schwetz, FDA Interim Chief Scientist.
The afternoon will be divided into three discussion groups, each of which will
be held three times, so that registrants can rotate to all three sessions.
Topics to be discussed will include:
- Enhancing the development of "emerging science" and its use in regulatory decisions.
- Bridging the communication gap between research and review scientists.
- Optimizing and leveraging FDA resources to enhance flexibility in problem-solving.
We anticipate some lively discussions, but we need your participation!!
Bring your ideas for enriching the relationship and interface between our
research and review/regulatory functions as a means of supporting FDA's
science base.
GETTING TO THE FORUM: TRANSPORTSION AND PARKING
You are strongly encouraged to use public transportation to NIH, as visitor parking is extremely limited.
Visitor parking fees are $2.00/hour with a 3-hour limit or $12.00/day.
The Medical Center Metro stop is very convenient to the Natcher Conference Center.
Map of the NIH Campus and Visitor Parking Locations.
INSTRUCTIONS FOR PREPARATION, SET-UP AND DISPLAY OF POSTERS:
Poster Preparation:
- Please indicate the affiliation of all FDA authors in the title (e.g., Center or Field Lab).
- In the body of the poster, please use text and graphics which are large enough to be
easily seen and understood from several feet away.
- Start with a short introduction which summarizes the rationale for the work you are
presenting.
- Number your panels or figures so the intended information flow is easily followed.
- Present your conclusions as a list of concise statements.
- Include your name and a means for contacting you (e.g., phone number, e-mail
address).
Poster Set-up and Take-down:
- The poster session will be held in the atrium and lower level conference rooms of the
Natcher Conference Center, NIH Campus, Bethesda, Maryland.
- Poster boards will be available beginning at 12:00 p.m. on December 8. The poster
session will take place from 2:00 - 5:00 p.m. on December 8, and all day (7:30 a.m. -
5:00 p.m.) on Dec. 9.
- Board number and room assignments will be posted at the registration table, listed
alphabetically by first author's last name.
- Push pins will be available at the door. If you need other fastening material, please
bring it with you.
- If possible, posters should be left up from 2:00 - 5:00 p.m. on December 8 and from
7:30 a.m. to 5:00 p.m. on December 9.
- Authors should be available for discussion at their posters
from 12:00 - 1:00 p.m. on December 9.
SIGMA XI POSTER SESSION
The Sigma Xi Poster Session will feature all areas of FDA research and
regulatory science. The session will begin on the afternoon of
December 8, and continue through the day on December 9.
Posters have been accepted in all categories of research and regulatory
science. Those categories include the following areas:
- Methods development and application: Analytical Chemistry
- Methods development and application: Biological Endpoints
- Methods development and application: Engineering and Physics
- Methods development and application: Post-market Surveillance
- Validation, Testing, Standardization and Quality Assurance
- Clinical Studies
- Molecular Biology
- Neurobiology/neurotoxicology
- Immunology
- Risk Assessment and Pre-Clinical Studies in vitro
- Risk Assessment and Pre-Clinical Studies in vivo
- Microbial Pathogens
- Reproductive Toxicology
Sigma Xi, FDA Chapter |
CFSAN/FDA Resource Page
Last updated on 2000-OCT-05 by frf